Compare KWR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | VCEL |
|---|---|---|
| Founded | 1918 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 1994 | 1996 |
| Metric | KWR | VCEL |
|---|---|---|
| Price | $169.53 | $43.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $167.00 | $57.75 |
| AVG Volume (30 Days) | 125.1K | ★ 454.1K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $1,888,634,000.00 | $276,259,000.00 |
| Revenue This Year | $5.16 | $19.40 |
| Revenue Next Year | $3.63 | $18.24 |
| P/E Ratio | $63.70 | ★ N/A |
| Revenue Growth | 2.66 | ★ 16.45 |
| 52 Week Low | $112.18 | $28.95 |
| 52 Week High | $183.01 | $49.32 |
| Indicator | KWR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 43.93 |
| Support Level | $132.58 | $32.44 |
| Resistance Level | $183.01 | $49.04 |
| Average True Range (ATR) | 7.00 | 1.53 |
| MACD | 0.39 | -0.39 |
| Stochastic Oscillator | 80.08 | 10.37 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.